Prostate Cancer

Decreases in local-stage and increases in distant- and regional-stage prostate cancer incidence may be the result of a recommendation by the US Preventive Services Task Force against PSA–based screenings.

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

External beam radiotherapy plus androgen deprivation therapy showed superior overall survival compared with EBRT plus a brachytherapy boost in men with intermediate- and high-risk prostate cancer.

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Neeraj Agarwal, MD, provides insight into olaparib, further discusses the data that led to the regulatory approval, and shares the implications of this approval in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, provides insight into olaparib, further discussed the data that led to the regulatory approval, and shared the implications of this approval in metastatic castration-resistant prostate cancer.

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Nicholas J. Vogelzang, MD, discusses the significance of the rucaparib approval for this patient population.

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

The FDA has approved rucaparib for the treatment of adult patients with BRCA-mutant recurrent, metastatic castration-resistant prostate cancer.

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

Alanna K. Rahm, PhD, MS, discusses the challenges of implementing alternate delivery models for genetic counseling in prostate cancer.

Elisabeth I. Heath, MD, FACP, discusses developments in nonmetastatic castration-resistant prostate cancer (CRPC).

Stephen J. Freedland, MD, discusses remaining questions with the real-world utility of enzalutamide in prostate cancer.

Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.

Celestia S. Higano, MD, FACP, discusses the state of immunotherapy in prostate cancer.

Eric Shinohara, MD, MSCI, discusses the potential to combine stereotactic body radiotherapy with immunotherapy in prostate cancer.

Karen E. Knudsen, PhD, chair and Hilary Koprowski Professor, Department of Cancer Biology, professor of cancer biology, urology, medical oncology, and radiation oncology, and enterprise director, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discusses DNA-dependent protein kinase (DNA-PK) as an emerging target in prostate cancer.